title: Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy.
abstract: There has been a recent emergence of novel targeted agents for treatment of Hodgkin and non-Hodgkin lymphoma. In particular, antibodies and antibody-drug conjugates directed against surface antigens, agents that block immune checkpoint pathways, and small molecule inhibitors directed against cell signaling pathways have shown significant promise in patients with relapsed and refractory disease and in the frontline setting. With the development of these new therapies, cytotoxic chemotherapy may be avoided entirely in some clinical settings. This review will present the latest information on these novel treatments in Hodgkin and non-Hodgkin lymphoma and will discuss both recently approved agents as well as drugs currently being studied in clinical trials.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7305, USA.
authors.forename: Natalie S
authors.initials: NS
authors.lastname: Grover
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7305, USA. sipark@med.unc.edu.
authors.forename: Steven I
authors.initials: SI
authors.lastname: Park
keywords: Hodgkin lymphoma; antibody-drug conjugates; immune-checkpoint inhibitors; monoclonal antibody; non-Hodgkin lymphoma; small molecule inhibitors